Experience with vandeta nib in medullary thyroid cancer

• Autores: José Manuel Caro Teller, Susana Cortijo Cascajares, Irene Escribano Valenciano, Olga Serrano Garrote, Juan Manuel Sepúlveda Sánchez
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 16, Nº. 6, 2014, págs. 10-10
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Medullary thyroid cancer (MTC) is caused by the uncontrolled growth of calcitonin secreting parafollicular cells accounting for 5% of all thyroid cancers. Vandetanib is the first tyrosine kinase inhibitor (TKI) that is indicated for locally advanced or metastatic MTC demonstrating clinical benefit in different trials for those patients with limited treatment options.

    Next, we introduce two cases undergoing MTC in which the treatment with vandetanib has achieved stabilization of the disease in one and a partial remission of the cancer in another, both with manageable adverse reactions.

    Conclusion: Vandetanib would be an effective therapeutic option in patients with advanced or metastatic MTC without the possibility of other treatment alternatives